SOURCE-LINKED STUDY SUMMARY
Efficacy and safety of once-weekly somatrogon in adults with growth hormone deficiency: a randomized phase 3 study.
Full paper summarizedQuality not appraised
- What was studied
- A randomized phase 3 trial evaluated long-acting growth hormone in adults with growth hormone deficiency.
- Who / model studied
- 202 adults were randomized; 198 received treatment.
- Studied dose & schedule
- Weekly subcutaneous somatrogon or placebo for 26 weeks, with individualized dose titration; subsequent extensions gave everyone somatrogon.
- What the study found
- The primary trunk-fat endpoint was not significant (-0.37 versus 0.03 kg; p=0.0821). Lean mass improved; adverse-event incidence was similar. Some favorable outcomes were post-hoc.
- Limitations & context
- The missed primary endpoint remains important. Body-composition changes do not establish strength gains or healthy-person enhancement. Extensions lacked a concurrent placebo group; no daily-GH comparator.
Read summary source ↗ · Prepared 10/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1007/s11102-026-01661-1